SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers |
| |
Authors: | Mills David A Fekrazad Houman M Verschraegen Claire F |
| |
Institution: | The University of New Mexico Cancer Center, 900 Camino de Salud, NE, Albuquerque, NM 87131, USA. |
| |
Abstract: | Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell cycle inhibitor and apoptosis stimulator, for the potential treatment of a variety of solid and hematological malignancies. Phase I clinical trials had been completed in several solid tumor types and phase II clinical trials had been completed in patients with small-cell lung cancer and NSCLC. A phase II clinical trial in patients with platinum-resistant ovarian cancer and phase I/II and phase II clinical trials in patients with acute leukemias were ongoing at the time of publication. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|